
    
      Main: to demonstrate the bioequivalence of the new buprenorphine transdermal patch T2rev
      formulation containing 13 mg buprenorphine (Test) as compared to Transtec (R) PRO 70 Âµg/h
      patch transdermal patch containing 40 mg buprenorphine as reference (Reference) after single
      patch application. Pharmacokinetic target parameters are AUC, AUCo-t, and Cmax.

      Further: To assess the safety, tolerability, skin tolerability and adhesiveness of the patch
      applications
    
  